Member Info for jona35

Or lose everything

After researching the company funding is needed and we all know what that means .but there is a lot to come here which on paper looks very good so for now the company's defo on my watch list for now .and as for going bust i dont think so

Points from last rns

1 Patent filed in a collaborative project with NeuroBio to support early diagnostics for Alzheimer's disease (Jun 2023)

2 Development of exemplification data, demonstrating Optimer® binders as IHC reagents for research and diagnostics is underway with promising early results (Oct 2023)

3The Company continues to see demand for its Optimer® technology from across the life sciences. Due to the continued demand for Optimer® binders and the Group's expertise in the affinity ligand industry, we believe we are well-placed to use the platform to build lower-risk fee-for-service revenues and drive positive momentum and revenue growth and to target opportunities to licence its technology to the developers of diagnostic tests and therapeutics.

4 The Board believes that outcomes of these research and development activities will enable further proof of the platform supporting the signing of high value, high impact, deals. Future higher-risk development work will, in whole or part, be funded via grants and collaborations to minimise the impact on working capital requirements. A collaboration with Bioliquid Innovative Genetics and Anima Design is a great example of such work, funded through the European Eurostars programme to support Optimer® development for an application in a novel prenatal and foetal diagnostic platform.

5 Within the period, the Company signed an agreement with Neuro-Bio to develop Optimer® binders against a novel biomarker for Alzheimer's disease. The Optimer® binders will be used to enable the development of a novel lateral flow test for the early diagnosis of Alzheimer's disease. This agreement has progressed successfully with a panel of binders being patented by Neuro-Bio. Further integration of the binders into a routine lateral flow test will support the clinical and commercial development of rapid diagnostics for Alzheimer's disease through simple nasal sampling.

6 Under the new management team, and with cash on the balance sheet, we have seen a significant improvement in customer confidence. The pipeline of opportunities that are at advanced stages of discussion currently stands at a healthy £3.3 million across 28 unique projects (subject to commercial and scientific attrition). Since the completion of the refinancing, we are encouraged to have added 128 new leads to a growing pool of opportunities which gives management confidence that significant orders will be signed before the 2023 calendar year end.

so then lots going on as you can see more than happy to hold here ...not to long to the end of 2023 expect some explosives' RNS to come before year end maybe tomorrow next week but i am dam sure there will be as they say buy the lows which is now but dyor

I have read the rns a number of times now the lost was before the fund raise..It seem to me they are hinting at M bag deals being worked we knew before the fund raise the information of a loss so nothing new there ..Going forwards i expect to see deals coming through very soon I have myself been buying at these levels as i can only see an upside from here..As they say get any bad news out first ..expect TR1 seller out shares flipped and read the RNS more than once you will pick up on things gla

Traders have no chance her we ground breaking news around the courner

In early trading on Monday, shares of Aptamer Group PLC (AIM:APTA) fell 11%, despite the company's announcement of operational progress and strategic advancements under its new management team.

In the update, investors were told the company has successfully streamlined production processes, passed an ISO 9001 audit with commendations, and made strides in Optimer-based technologies for the immunohistochemistry market and targeted drug delivery systems

Seller gone then lol...just got loads of shares there love it when people don't read the RNS correct the small down side was before the funding you Muppets look at the market cap and read it again i see the trolls are here ignor . 128 new leads to a growing pool of opportunities which gives management confidence that significant orders will be signed before the 2023 calendar year end."

Welcome you may also find some good research on my prev posts just to give you a start.got to shot off now

17 August 2023

Aptamer Group plc

("Aptamer Group", "APTA" or the "Company")

Result of General Meeting

Update on Fundraise, Strategy, Board Changes, Change of Broker, Broker Research Marketing Communication and PDMR Dealings

Aptamer Group (AIM:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce that, further to the Company's announcement on 31 July 2023, at its general meeting held today, all resolutions were passed.

Accordingly, all of the proposals set out in the circular dated 31 July 2023 will proceed.

Fundraise

Further to the Company's announcement on 31 July 2023, following shareholder approval at the general meeting today, the Company has successfully raised £3.6 million (before costs) by way of a Placing and Subscription. The Company intends to use the net proceeds of the Fundraise for working capital purposes, with the aim of reaching an EBITDA and cash break even position within two years.

In aggregate, 370,000,000 new Ordinary Shares have been issued at a price of 1p each in connection with the Fundraise, of which 10,318,390 new Ordinary Shares were admitted to trading on AIM on 4 August 2023 and the remaining 359,681,610 new Ordinary Shares are expected to be admitted to trading on AIM on 21 August 2023.

Certain of the existing Directors, all of the of Proposed Directors and certain senior managers have participated in the Fundraise, contributing £269,900 in aggregate to the total raised. Following completion of the Fundraise, the continuing board and certain senior managers will hold in aggregate approximately 12.37 per cent of the issued share capital.

Strategy

The Company will focus on tight costs discipline with the intention of reaching an EBITDA and cash break even position within two years.

Consequently, budgeted costs for premises, overheads and development, directors and staff are targeted to be reduced from approximately £6.4 million (unaudited) in the year ended 30 June 2023 to approximately £3.5 million for the current financial year. This reset of the cost base is expected to be completed by the end of September 2023 with a reduction in operational headcount to the level required to meet forecasted revenues over the next several years.

Research and development activities will focus on process improvements to reduce delivery timelines or increase margins, cost reduction activities, and driving recurring revenues through customer support. It is intended that higher risk development work will in whole or part be funded via grants and collaborations that will be sought to minimise the impact on working capital requirements.

Pml really .you cant be that stupid can you your winding me up for sure lol what do you think the holding rns are lol

Or also missing the other 3.6 million raised as the 300k so they have just under 4 million in cash

Well not for about 17 months but if the alzheimer's nasal diagnostic test being in developed t and all the other stuff going on they may never need to ..there is a big campaign going on at the moment with the company doing shows all over the world.so they are getting the company out on the world stage. Big contracts will come via RNS the rest will be out in there report which was oct last year ..if you want to know more check out the past RNS hope this helps

RNS Number : 9603M

Aptamer Group PLC

19 September 2023

19 September 2023

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Placing and Subscription to raise £310,772

PDMR Dealing

Total Voting Rights

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has raised £310,772 through the issue of 28,251,956 new Ordinary Shares by way of a subscription and a placing by Turner Pope to certain existing shareholders at 1.1p per share (the "Issue Price") (together, the "Fundraise").

The Fundraise was initiated following approaches from existing non-UK shareholders who could not be contacted in time to participate in the August 2023 fundraise and extended to take advantage of demand from other existing shareholders using the Company's remaining net authorised unissued share capital.

The Fundraise includes a subscription by Dr Adam Hargreaves, a non-executive director of the Company, for 5,000,000 new Ordinary Shares for a total investment of £55,000. Following this further investment, Dr Hargreaves is now interested in 22,500,000 Ordinary Shares representing 4.81 per cent of the enlarged issued share capital.

In addition, an existing investor, Mr Nicholas Slater, is investing £50,000 in the Fundraise for 4,545,454 new Ordinary Shares, taking his holding to 26,045,454 Ordinary Shares representing 5.57% of the enlarged issued share capital.

The net proceeds will be ringfenced to support research and development (R&D) activities within the business, including the ongoing process improvements. R&D work was reduced as part of the Company's new strategy to support cost-cutting in August. While higher-risk development activities will still aim to be funded by grants, the new funds will enable internal validation of the technology in key focus areas.

Total Voting Rights

31 July 2023

Aptamer Group plc

("Aptamer Group", "APTA" or the "Company")

Update on Strategic Review and Formal Sale Process

Aptamer Group (AIM:APTA), the developer of novel Optimer® binds to enable innovation in the life sciences industry, provides an update regarding the Strategic Review and Formal Sale Process announced on 26 July 2023.

Earlier today, the Company announced a conditional fundraising of £3.6 million. Accordingly, the board has decided to terminate the Formal Sale Process under the City Code on Takeovers and Mergers (the "Takeover Code"). The Company is not in discussions with any party in relation to a sale and is not in receipt of any approaches. Accordingly, the Company is no longer in an offer period and the requirement to make disclosures under Rule 8 of the Takeover Code has now ceased.

For further information, please contact:

We have just fund raised and are good for 17 months so your totally wrong there we are fully funded plus posable grants..maybe you should do your homework and research before you post

Post-year end highlights

· Multiple contracts signed with a top ten pharmaceutical company to develop Optimer® binders for bioprocessing to support purification of novel therapeutics

· Contract signed with a multi-national consumer goods company for the development of Optimer® binders as novel solutions in personal care

· Agreement with leading US-based biotech company for the development of Optimer® binders to remove bioprocessing contaminants during therapeutic production

· Partnership with a top ten pharmaceutical company to develop Optimer® binders as immunohistochemistry reagents to support pipeline assets and early discovery targets

· Contract signed with Bioliquid Innovative Genetics S.L. to support Optimer® development for a novel prenatal and placental diagnostic platform

just some of the report from oct last year .on a personal note i am excited to see how far we have come since then as we are working with big phama companies

Also remember from last years report there was lots of news and updates all in one... its seems there waiting for something before it comes ..also remember small contracts don't have to be RNS they will be all together in report like last years

Up she goes 1.37 paid

News ? buys 1.34 now somethings brewing again

Off a higher low is always a good sign flipping of share complete yet well its about time